Paul Emesz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Emesz has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Sophie Brunner
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
2 shared publications - Nikolaus Luft
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
2 shared publications - Siegfried Georg Priglinger
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
2 shared publications - Stefan Kassumeh
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
2 shared publications - Andreas Ohlmann
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
1 shared publication - Jascha Wendelstein
University Eye Hospital Ludwig‐Maximilians‐University Munich Germany
1 shared publication
Latest Publications
- Open Access
Impact of Iris Color and Laterality on Lenticule Extraction Time in Keratorefractive Lenticule Extraction (KLEx)
Purpose: This study aims to evaluate the effects of iris color and laterality on keratorefractive lenticule extraction (KLEx) surgery time. Setting: A retrospective analysis was conducted on 656 eyes of 328 patients undergoing small incision lenticule extraction (SMILE). Mean patient age was 32 ± 7 years. Methods: Preoperative parameters, including manifest refraction spherical equivalent (MRSE), refractive cylinder, and corrected distance visual acuity (CDVA), were measured. Iris color was classified as “light” (n = 390) or “dark” (n = 266) by a senior ophthalmologist as the grader. Surgical time was determined from video recordings, defined as the time between opening of the KLEx incision and extraction of the lenticule. The surgery was performed by a single highly experienced, right-handed refractive surgeon. Results: Eyes with light irides showed significantly shorter lenticule extraction times than those with dark irides (75 ± 22 s vs. 90 ± 31 s, p < 0.0001). No statistically significant differences were found between eyes with light and dark irides in terms of postoperative MRSE, refractive cylinder, uncorrected distance visual acuity (UDVA), CDVA, safety and efficacy index, respectively (p > 0.05 for all). Surgical time was significantly shorter in right eyes compared to left eyes (74 ± 25 s vs. 89 ± 27 s, p < 0.0001). When analyzing laterality and iris color, surgery was shortest in right eyes with light irides (68 ± 19 s) and longest in left eyes with dark irides (97 ± 31 s; p < 0.0001). Conclusions: SMILE surgery took significantly less time in patients with light irides and in the right eyes compared to dark irides and the left eyes. These findings suggest that patients’ iris color and laterality in relation to surgeon handedness may influence the ease of surgical lenticule extraction to a comparable extent.
Open AccessImpact of Iris Color and Laterality on Lenticule Extraction Time in Keratorefractive Lenticule Extraction (KLEx)
Purpose: This study aims to evaluate the effects of iris color and laterality on keratorefractive lenticule extraction (KLEx) surgery time. Setting: A retrospective analysis was conducted on 656 eyes of 328 patients undergoing small incision lenticule extraction (SMILE). Mean patient age was 32 ± 7 years. Methods: Preoperative parameters, including manifest refraction spherical equivalent (MRSE), refractive cylinder, and corrected distance visual acuity (CDVA), were measured. Iris color was classified as “light” (n = 390) or “dark” (n = 266) by a senior ophthalmologist as the grader. Surgical time was determined from video recordings, defined as the time between opening of the KLEx incision and extraction of the lenticule. The surgery was performed by a single highly experienced, right-handed refractive surgeon. Results: Eyes with light irides showed significantly shorter lenticule extraction times than those with dark irides (75 ± 22 s vs. 90 ± 31 s, p < 0.0001). No statistically significant differences were found between eyes with light and dark irides in terms of postoperative MRSE, refractive cylinder, uncorrected distance visual acuity (UDVA), CDVA, safety and efficacy index, respectively (p > 0.05 for all). Surgical time was significantly shorter in right eyes compared to left eyes (74 ± 25 s vs. 89 ± 27 s, p < 0.0001). When analyzing laterality and iris color, surgery was shortest in right eyes with light irides (68 ± 19 s) and longest in left eyes with dark irides (97 ± 31 s; p < 0.0001). Conclusions: SMILE surgery took significantly less time in patients with light irides and in the right eyes compared to dark irides and the left eyes. These findings suggest that patients’ iris color and laterality in relation to surgeon handedness may influence the ease of surgical lenticule extraction to a comparable extent.
- Open Access
Deferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression
Background and Objectives: The objective of this study is to evaluate whether deferoxamine modulates cell biological properties, such as proliferation and wound closure of porcine corneal endothelial cells (CECs) in vitro, and whether the treatment of CECs with deferoxamine results in an enhanced expression of vascular endothelial growth factor (VEGF). Materials and Methods: Corneal endothelial cells were extracted from porcine globes within 24 h postmortem. Immunohistochemistry for the endothelial Na+/K+-ATPase was performed to confirm the cells’ endothelial origin. To assess CEC viability and proliferation, a water-soluble tetrazolium salt (WST-1) and 5-bromo-2′-deoxyuridine (BrdU) assay were performed. Corneal endothelial wound closure was evaluated using a wound closure assay. VEGF mRNA expression was evaluated using real-time polymerase chain reaction (rt-PCR). Results: The extracted corneal endothelial cells showed a typical hexagonal morphology with Na+/K+-ATPase staining of the cell membrane. The treatment with 200 µM deferoxamine significantly increased CEC viability to 121 ± 24% compared to the control group (p = 0.0024). Corneal endothelial cell proliferation did not show any significant changes under the treatment with deferoxamine (p > 0.05). Both 100 µM and 200 µM deferoxamine led to a significantly smaller remaining wound area of 82.4 ± 6.7% and 78.7 ± 6.2% (p < 0.0001) in comparison to the control group after 24 h of treatment in the wound closure assay. Treatment with 200 µM deferoxamine significantly induced VEGF mRNA expression to 1.67- ± 0.57-fold from 1.00- ± 0.03-fold in the control group (p = 0.0006). Conclusions: Deferoxamine effectively enhances corneal endothelial cell viability and wound healing associated with an overexpression of VEGF. Thus, deferoxamine is a potent modulator of cell biological properties of corneal endothelial cells and maintains their integrity in vitro.
Open AccessDeferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression
Background and Objectives: The objective of this study is to evaluate whether deferoxamine modulates cell biological properties, such as proliferation and wound closure of porcine corneal endothelial cells (CECs) in vitro, and whether the treatment of CECs with deferoxamine results in an enhanced expression of vascular endothelial growth factor (VEGF). Materials and Methods: Corneal endothelial cells were extracted from porcine globes within 24 h postmortem. Immunohistochemistry for the endothelial Na+/K+-ATPase was performed to confirm the cells’ endothelial origin. To assess CEC viability and proliferation, a water-soluble tetrazolium salt (WST-1) and 5-bromo-2′-deoxyuridine (BrdU) assay were performed. Corneal endothelial wound closure was evaluated using a wound closure assay. VEGF mRNA expression was evaluated using real-time polymerase chain reaction (rt-PCR). Results: The extracted corneal endothelial cells showed a typical hexagonal morphology with Na+/K+-ATPase staining of the cell membrane. The treatment with 200 µM deferoxamine significantly increased CEC viability to 121 ± 24% compared to the control group (p = 0.0024). Corneal endothelial cell proliferation did not show any significant changes under the treatment with deferoxamine (p > 0.05). Both 100 µM and 200 µM deferoxamine led to a significantly smaller remaining wound area of 82.4 ± 6.7% and 78.7 ± 6.2% (p < 0.0001) in comparison to the control group after 24 h of treatment in the wound closure assay. Treatment with 200 µM deferoxamine significantly induced VEGF mRNA expression to 1.67- ± 0.57-fold from 1.00- ± 0.03-fold in the control group (p = 0.0006). Conclusions: Deferoxamine effectively enhances corneal endothelial cell viability and wound healing associated with an overexpression of VEGF. Thus, deferoxamine is a potent modulator of cell biological properties of corneal endothelial cells and maintains their integrity in vitro.
- 1 April 2026
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 168 (6) , 60-66
Verletzungen am Auge
- 1 April 2026
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 168 (6) , 60-66
Verletzungen am Auge